Author + information
- Adam Benjafielda,b,
- JoAnn Lindenfelda,b,
- Olaf Oldenburga,b,
- David Whellana,b,
- Mona Fiuzata,b,
- Naresh Punjabia,b,
- Kevin Anstroma,b,
- Amy Blasea,b and
- Holger Woehrlea,b
Background: The CAT-HF trial was designed to evaluate outcomes in hospitalized heart failure patients with HFrEF and HFpEF with moderate to severe sleep apnea, randomized to adaptive servo-ventilation (ASV) or usual care (OMT). The primary endpoint of CAT-HF was a global rank composite of death, cardiovascular hospitalizations, and 6 minute walk distance at 6 months. The objective was to determine if surrogate endpoints such as changes in natriuretic peptide (NT pro-BNP) and quality of life (KCCQ) predict a differential response to treating sleep apnea with ASV in patients with HFrEF and HFpEF.
Methods: Changes in secondary “surrogate” endpoints of NT pro-BNP and KCCQ were compared by EF group stratified as HFrEF ≤ 45% and HFpEF >45%.
Results: There was no significant change in the global rank score for the HFrEF subgroup (p-value = 0.40) but was significantly improved for HFpEF subgroup (p-value = 0.036). Matched pair changes for both NT pro-BNP and KCCQ were not significantly different (Table). There appeared to be a reversal in the trend for the magnitude of change when comparing EF status with non-significant improvements larger for the ASV group in HFpEF, and OMT in HFrEF.
Conclusions: Surrogate endpoints of changes in NT pro-BNP and KCCQ appeared to track with the differences in global rank score in HFpEF compared to HFrEF, though was not significant and suggests that treating sleep apnea may be different depending on the EF status. This should be further evaluated in future trials.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Heart Failure and Cardiomyopathies: Is Heart Failure With a Normal EF for Real?
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1121-250
- 2017 American College of Cardiology Foundation